80 completed. 80 Phase 2, 22 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 80 | Completed 80 |
| Phase 1 | 22 | Completed 22 |
Follow Mantle Cell Lymphoma: new trials by email Literature Review of Mantle Cell Lymphoma trials Research Report on Mantle Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating Different Doses of Orelabrutinib in MCL Orelabrutinib High dose, Orelabrutinib Low dose - Mantle Cell Lymphoma | Phase 2 | Completed | InnoCare Pharma Inc. | 40 | 2023-08-18 | 2026-06-11 |
| Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma Acalabrutinib - Mantle Cell Lymphoma | Phase 2 | Completed | SCRI Development Innovations, LLC | 15 | 2020-08-07 | 2025-05-13 |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab BGB-10188, Zanubrutinib, Tislelizumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | BeiGene | 97 | 2020-04-29 | 2026-02-20 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia TC-110 T Cells, Fludarabine, Cyclophosphamide - Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Completed | TCR2 Therapeutics | 6 | 2020-03-27 | 2023-03-16 |
| Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age Venetoclax, Bendamustine, Rituximab - Mantle Cell Lymphoma | Phase 2 | Completed | PrECOG, LLC. | 33 | 2020-01-13 | 2025-08-11 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Fludarabine, Melphalan, Total Body Irradiation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2019-12-06 | 2025-12-11 |
| Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Zanubrutinib - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma | Phase 2 | Completed | BeiGene | 96 | 2019-10-15 | 2026-01-28 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine - Malignancy, Non-hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Cyteir Therapeutics, Inc. | 169 | 2019-10-09 | 2024-12-24 |
| Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) Acalabrutinib 2x100 MG Oral Capsule + alloSCT - Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease | Phase 2 | Completed | Polish Lymphoma Research Group | 29 | 2019-08-19 | 2025-01-16 |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL Pirtobrutinib, Venetoclax, Rituximab - Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia | Phase 1 / Phase 2 | Completed | Loxo Oncology, Inc. | 803 | 2019-03-15 | 2026-01-27 |
| Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma Bendamustine, Rituximab, Acalabrutinib - Mantle Cell Lymphoma | Phase 2 | Completed | Washington University School of Medicine | 13 | 2018-11-29 | 2026-04-21 |
| A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) ICP-022 - Mantle Cell Lymphoma | Phase 1 / Phase 2 | Completed | Beijing InnoCare Pharma Tech Co., Ltd. | 106 | 2018-04-02 | 2026-06-08 |
| A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies Cirmtuzumab (2-16 kg/mg) plus Ibrutinib, Cirmtuzumab (300mg) plus Ibrutinib, Cirmtuzumab (600 mg) plus ibrutinib - B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Completed | Oncternal Therapeutics, Inc | 95 | 2018-01-03 | 2025-02-12 |
| Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cord Blood-derived Expanded Allogeneic Natural Killer Cells - Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 22 | 2017-10-10 | 2023-02-16 |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma Entospletinib, Laboratory Biomarker Analysis, Obinutuzumab - Anemia, B-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | Alexey Danilov, MD | 24 | 2017-07-17 | 2023-08-08 |
| High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant Busulfan, Cyclophosphamide, Fludarabine Phosphate - Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Completed | City of Hope Medical Center | 38 | 2017-05-30 | 2024-01-09 |
| Efficacy of Upfront and Maintenance Obinutuzumab in Mantle Cell Lymphoma Treated by DHAP and MRD Driven Maintenance Obinutuzumab, Dexamethasone, Aracytine - Mantle Cell Lymphoma | Phase 2 | Completed | The Lymphoma Academic Research Organisation | 86 | 2016-11-29 | 2026-01-14 |
| TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma Ibrutinib, Radiation Therapy, TLR9 Agonist SD-101 - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 21 | 2016-11-07 | 2024-10-16 |
| Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma Bortezomib, Cytarabine, Dexamethasone, Pegteograstim - Mantle Cell Lymphoma | Phase 2 | Completed | Seoul National University Hospital | 19 | 2016-10-11 | 2023-03-20 |
| Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma Lenalidomide, R-CHOP, high-dose cytarabine (HIDAC) - Mantle Cell Lymphoma, Untreated | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 49 | 2015-12-14 | 2024-08-30 |
Showing 20 of 80. Sign in to see all of them.
Lymphoma, Mantle-Cell (80) · Lymphoma, Follicular (19) · Lymphoma, Non-Hodgkin (19) · Leukemia, Lymphocytic, Chronic, B-Cell (18) · Lymphoma, Large B-Cell, Diffuse (16) · Lymphoma, B-Cell, Marginal Zone (14) · Lymphoma (11) · Burkitt Lymphoma (6) · Lymphoma, B-Cell (6) · Hodgkin Disease (5) · Multiple Myeloma (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Waldenstrom Macroglobulinemia (5) · Leukemia, Myeloid, Acute (4) · Leukemia, B-Cell (3)
Hemic and Lymphatic Diseases (80) · Immune System Diseases (80) · Immunoproliferative Disorders (80) · Lymphatic Diseases (80) · Lymphoproliferative Disorders (80) · Neoplasms by Histologic Type (80) · Neoplasms (78) · Lymphoma (69) · Lymphoma, Non-Hodgkin (61) · Hematologic Diseases (23) · Lymphoma, B-Cell (22) · Leukemia (20) · Disease Attributes (19) · Leukemia, Lymphoid (19) · Pathologic Processes (19)
Rituximab (30) · Bortezomib (12) · Lenalidomide (11) · Bendamustine Hydrochloride (10) · Cytarabine (10) · Cyclophosphamide (9) · Melphalan (7) · Vincristine (7) · ibrutinib (7) · Dexamethasone (5) · Doxorubicin (5) · Etoposide (5) · Whole-Body Irradiation (5) · fludarabine phosphate (5) · Carmustine (4)
M.D. Anderson Cancer Center (4) · Fondazione Italiana Linfomi - ETS (3) · Fred Hutchinson Cancer Center (3) · Memorial Sloan Kettering Cancer Center (3) · Millennium Pharmaceuticals, Inc. (3) · BeiGene (2) · Celgene (2) · French Innovative Leukemia Organisation (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · National Cancer Institute (NCI) (2) · Pharmacyclics LLC. (2) · SCRI Development Innovations, LLC (2) · University of Wisconsin, Madison (2) · AbbVie (prior sponsor, Abbott) (1) · Acrotech Biopharma Inc. (1)
United States (55) · France (11) · United Kingdom (8) · Italy (7) · Spain (6) · Germany (5) · Poland (5) · Canada (4) · Belgium (3) · China (3) · Denmark (3) · Israel (3) · Sweden (3) · Australia (2) · Hungary (2)
Brad S Kahl, MD (2) · Anas Younes, MD (1) · Andrew Zelenetz, MD,PhD (1) · Anita Kumar, MD (1) · Ann E. Dahlberg (1) · Anna Laurell, MD (1) · Arne Kolstad, MD (1) · Brad S Kahl, M.D. (1) · Brenda Sandmaier (1) · Carlo Visco, MD (1) · Carlos Grande, MD (1)
PMID 17242396, PMID 34398557, PMID 12620412, PMID 12907446, PMID 16116429, PMID 16123218, PMID 16766582, PMID 17299095, PMID 20220059, PMID 20626754, PMID 20956803, PMID 22058200, PMID 23782157, PMID 23940282, PMID 24019544, PMID 24048792, PMID 24652994, PMID 24919854, PMID 25016003, PMID 25361987, PMID 25381051, PMID 25921098, PMID 26059948, PMID 26535512, PMID 27354719, PMID 27750483, PMID 27927586, PMID 28408615, PMID 28699256, PMID 28771673, PMID 29056470, PMID 29234922, PMID 29437592, PMID 30082475, PMID 30181173, PMID 31196847, PMID 31371411, PMID 32209572, PMID 32603426, PMID 32800518, PMID 32971036, PMID 33181832, PMID 33236943, PMID 33558202, PMID 33676628, PMID 34156440, PMID 34196037, PMID 34780125, PMID 35143622, PMID 35595730
2005 (2), P30CA015704 (2), 2014 (1), 2018 (1), P01CA018029 (1), P30CA023074 (1), R35CA197353 (1)